You can have confidence in your biosimilar medicines

The provincial government is improving the sustainability of its public drug plans by expanding the use of biosimilars. In consultation with their physicians, about 3,000 beneficiaries of the province’s drug plans who are living with diseases such as inflammatory arthritis, inflammatory bowel disease, diabetes and psoriasis will have until Nov. 30 to switch from an originator biologic to the biosimilar version. 

Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, today congratulated the Government of New Brunswick for implementing a biosimilar “switching” or transitioning policy to expand the use of biosimilar medicines under the province’s public drug plans.

Coverage by The Center for Biosimilars of the adalimumab phase of the BC’s biosimilars program.